PAVmed Inc. (FRA:1P5)
Germany · Delayed Price · Currency is EUR | Market Cap | 13.55M +39.5% |
| Revenue (ttm) | 98.03K -89.0% |
| Net Income | -18.05M |
| EPS | -8.80 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5 |
| Open | 1.756 |
| Previous Close | 1.800 |
| Day's Range | 1.756 - 1.934 |
| 52-Week Range | 1.756 - 7.371 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About PAVmed
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, incl... [Read more]
News
Lucid Diagnostics begins receiving Medicare reimbursement for EsoGuard
Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that it has begun receiving payments from Medicare for its EsoGuard Esophageal DNA Test. The company also closed a $15M private…
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate Series C Preferred Stock private placement with existing long-term shareh...
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a new Category III CPT code for non...
PAVmed price target raised to $57 from $56 at Ascendiant
Ascendiant analyst Edward Woo raised the firm’s price target on PAVmed (PAVM) to $57 from $56 and keeps a Buy rating on the shares. The firm views the company’s Q2…
PAVmed reports Q2 adjusted EPS (27c) vs. ($1.40) last year
Reports Q2 revenue $33,000 vs. $6,000 last year. “PAVmed (PAVM) saw tangible progress across its core businesses during this past quarter and recent weeks,” said Lishan Aklog, M.D., PAVmed’s Chairman…
PAVmed Earnings Call Transcript: Q2 2026
Progress across all business segments, with Lucid advancing reimbursement, Veris accelerating commercial rollout at OSU, and PortIO achieving positive clinical results. Q2 GAAP net loss was $5.5M, with cash at $3.8M and significant financing activities completed.
PAVmed Quarterly report: Q2 2026
PAVmed has published its Q2 2026 quarterly earnings report on August 14, 2026.
PAVmed Slides: Q2 2026
PAVmed has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 14, 2026.
PAVmed Earnings release: Q2 2026
PAVmed released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics s...
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy Conference call and webcast to be held today, August 13...
Lucid announces Concert issued positive coverage policy for EsoGuard test
Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for n...
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteria NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the...
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed In...
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, op...
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagn...
PAVmed trading halted, volatility trading pause
09:40 EDT PAVmed (PAVM) trading halted, volatility trading pause
PAVmed reports Q1 non-GAAP EPS ($1.17) vs. ($1.97) last year
Reports Q1 revenue $22,000 vs. $8,000 last year. PAVmed (PAVM) had cash and cash equivalents of $6.5M as of March 31, compared to $1.5M as of December 31, 2025. “PAVmed…
PAVmed Earnings Call Transcript: Q1 2026
Restructuring completed, simplifying capital structure and enabling growth across diversified life sciences segments. Lucid and Veris subsidiaries are advancing toward key milestones, with Lucid nearing Medicare coverage and Veris expanding its commercial rollout.
PAVmed Quarterly report: Q1 2026
PAVmed has published its Q1 2026 quarterly earnings report on May 15, 2026.
PAVmed Slides: Q1 2026
PAVmed has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 15, 2026.
PAVmed Earnings release: Q1 2026
PAVmed released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnostics continued building commercial momentum and strengthened ...
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement miles...